VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ At least 18 years of age at the time of screening  │ At least 18 years of age at the time of screening  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have stable renal function for one month (30 days) │ Have stable renal function for one month (30 days) │     100 │
│ prior to enrollment                                │ prior to enrollment                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Documented genotype 1 HCV infection prior to       │ Documented genotype 1 HCV infection prior to       │     100 │
│ enrollment and after their transplant in the post- │ enrollment and after their transplant in the post- │         │
│ transplantation cohort                             │ transplantation cohort                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HCV disease staging within 12 months prior to      │ HCV disease staging within 12 months prior to      │     100 │
│ enrollment by liver biopsy, transient              │ enrollment by liver biopsy, transient              │         │
│ elastography, or biochemical testing               │ elastography, or biochemical testing               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Be able to give informed consent and comply with   │ Be able to give informed consent and comply with   │     100 │
│ study guidelines                                   │ study guidelines                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of childbearing age will be required to have │ Women of childbearing age will be required to have │     100 │
│ a negative pregnancy test at enrollment and use    │ a negative pregnancy test at enrollment and use    │         │
│ birth control throughout the duration of treatment │ birth control throughout the duration of treatment │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ On the transplant waiting list followed by the     │ On the transplant waiting list followed by the     │     100 │
│ University of Maryland's nephrology clinic or the  │ University of Maryland's nephrology clinic or the  │         │
│ Baltimore VA's nephrology clinic                   │ Baltimore VA's nephrology clinic                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ On chronic hemodialysis not yet on the transplant  │ On chronic hemodialysis not yet on the transplant  │     100 │
│ list and followed in the University's hemodialysis │ list and followed in the University's hemodialysis │         │
│ center or in the University's nephrology clinic    │ center or in the University's nephrology clinic    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Documented positive hepatitis B (HBV) surface      │ Documented positive hepatitis B (HBV) surface      │     100 │
│ antigen, and/or HBV DNA prior to enrollment        │ antigen, and/or HBV DNA prior to enrollment        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any prior exposure to HCV protease inhibitor       │ Any prior exposure to HCV protease inhibitor       │     100 │
│ therapy                                            │ therapy                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HIV co-infection if on a protease inhibitor based  │ HIV co-infection if on a protease inhibitor based  │     100 │
│ regimen                                            │ regimen                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Increase in creatinine of 15% or greater within    │ Increase in creatinine of 15% or greater within    │     100 │
│ one month (30 days) of the screening visit         │ one month (30 days) of the screening visit         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of hepatocellular carcinoma at the time   │ Evidence of hepatocellular carcinoma at the time   │     100 │
│ of enrollment                                      │ of enrollment                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver disease caused by an etiology other than HCV │ Liver disease caused by an etiology other than HCV │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ F4 or decompensated cirrhotic patients             │ F4 or decompensated cirrhotic patients             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Child Pugh class B or C                            │ Child Pugh class B or C                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of clinically significant allergy or       │ History of clinically significant allergy or       │     100 │
│ adverse event with protease inhibitors             │ adverse event with protease inhibitors             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of the acquisition of HCV at the time of  │ Evidence of the acquisition of HCV at the time of  │     100 │
│ or after transplantation                           │ or after transplantation                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or breastfeeding women                    │ Pregnant or breastfeeding women                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cyclosporine; St. John's Wort; Efavirenz;          │ Cyclosporine; St. John's Wort; Efavirenz;          │     100 │
│ Phenytoin; Carbamazepine; Bosentan; HIV protease   │ Phenytoin; Carbamazepine; Bosentan; HIV protease   │         │
│ inhibitors; modafinil; ketoconazole; or rifampin   │ inhibitors; modafinil; ketoconazole; or rifampin   │         │
│ use within 7 days of enrollment                    │ use within 7 days of enrollment                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Coadministration of more than 20 mg atorvastatin;  │ Coadministration of more than 20 mg atorvastatin;  │     100 │
│ 10 mg rosuvastatin; 20 mg of fluvastatin,          │ 10 mg rosuvastatin; 20 mg of fluvastatin,          │         │
│ lovastatin or simvastatin                          │ lovastatin or simvastatin                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have Chronic HCV infection prior to                │ Have Chronic HCV infection prior to                │      99 │
│ transplantation with documented HCV viremia ≥      │ transplantation with documented HCV viremia =      │         │
│ 1,000 IU/ml at screening and either documented HCV │ 1,000 IU/ml at screening and either documented HCV │         │
│ Ab positivity or HCV viremia ≥ 1,000 IU/ml at      │ Ab positivity or HCV viremia = 1,000 IU/ml at      │         │
│ least 6 months prior to enrollment                 │ least 6 months prior to enrollment                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have chronic kidney disease with GFR \<50          │ Have chronic kidney disease with GFR <50           │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ AST or ALT \>350 within 6 months prior to          │ AST or ALT >350 within 6 months prior to           │      99 │
│ enrollment                                         │ enrollment                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Albumin \< 3g/dL at the time of enrollment         │ Albumin < 3g/dL at the time of enrollment          │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Platelet count \< 75 at the time of enrollment     │ Platelet count < 75 at the time of enrollment      │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Patients will either be                            │ Pregnant or breastfeeding women                    │      41 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Albumin < 3g/dL at the time of enrollment          │      41 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inclusion Criteria Specific to the Pre-transplant  │ Evidence of the acquisition of HCV at the time of  │      47 │
│ Arm                                                │ or after transplantation                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inclusion Criteria Specific to the Post-transplant │ Evidence of the acquisition of HCV at the time of  │      47 │
│ Arm                                                │ or after transplantation                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ • Patients will have undergone renal               │ On chronic hemodialysis not yet on the transplant  │      47 │
│ transplantation no greater than five years prior   │ list and followed in the University's hemodialysis │         │
│ to enrollment and will be followed in our          │ center or in the University's nephrology clinic    │         │
│ University's nephrology and infectious disease     │                                                    │         │
│ clinic. They will all have stable renal function   │                                                    │         │
│ at the time of enrollment                          │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 91
Average Levenshtein Ratio of individual lines: 90.90322580645162
OverAll Ratio: 90.95161290322581
